No Data
No Data
Tempest Therapeutics Announces FDA Granted ODD to TPST-1495
Express News | Tempest Therapeutics Inc - Data From Phase 2 Study Expected in 2026
Express News | Tempest Receives Orphan Drug Designation From the FDA for Tpst-1495 to Treat Patients With Fap
Tempest Receives Orphan Drug Designation From the FDA for TPST-1495 to Treat Patients With FAP
Express News | Tempest Therapeutics Inc - to Reduce Workforce by 21 of 26 Employees - SEC Filing
Express News | Tempest Therapeutics Inc - on April 17 Adopts Plan to Extend Capital Resources - SEC Filing